Furthermore, IL-17 and IL-6 play an important role in Th2-low asthma and therefore a co-treatment with DCQAs might also be beneficial in reducing inflammation during this severe respiratory disease (Ramakrishnan et al., 2019; Habib et al., 2022). Here, IL6 is linked to asthma.